S-nitrosothiols are endogenous molecules that store and transduce nitric oxide, and are critical modulators of airway and vascular smooth muscle tone.
Charles Scoggin, chairman of N30 Pharma, said: “I am extremely pleased to announce this agreement. NitroMed is a leader in exploring the medical utility of nitric oxide and s-nitrosothiol therapies, and has foundational intellectual property in the area.”